Deutsche Bank AG Analysts Give Sanofi SA (SAN) a €96.00 Price Target
Other equities research analysts also recently issued research reports about the company. J P Morgan Chase & Co set a €95.00 ($111.76) price target on Sanofi SA and gave the stock a neutral rating in a research report on Thursday, June 22nd. Credit Suisse Group set a €95.00 ($111.76) price target on Sanofi SA and gave the stock a buy rating in a research report on Tuesday, July 4th. Goldman Sachs Group Inc set a €82.00 ($96.47) price target on Sanofi SA and gave the stock a neutral rating in a research report on Wednesday, July 26th. Kepler Capital Markets set a €89.00 ($104.71) price target on Sanofi SA and gave the stock a buy rating in a research report on Wednesday, July 26th. Finally, S&P Global set a €90.00 ($105.88) price target on Sanofi SA and gave the stock a neutral rating in a research report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and five have assigned a buy rating to the company. The company has an average rating of Hold and a consensus target price of €88.12 ($103.67).
Shares of Sanofi SA (EPA SAN) opened at 83.81 on Wednesday. Sanofi SA has a one year low of €24.55 and a one year high of €84.55. The stock’s 50 day moving average price is €26.13 and its 200 day moving average price is €26.02. The firm has a market cap of €105.24 billion and a price-to-earnings ratio of 11.69.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/10/22/deutsche-bank-ag-analysts-give-sanofi-sa-san-a-96-00-price-target.html.
About Sanofi SA
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Stock Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related stocks with our FREE daily email newsletter.